

FDA Recognized Abbreviated Blood Donor History Questionnaire (aDHQ) v2.1

AABB ACCREDITED BLOOD COLLECTION FACILITIES SHOULD USE THE FOLLOWING FDA RECOGNIZED aDHQ v2.1, with PrEP/PEP/ART including injectable PrEP:

- This aDHQ v2.1 is consistent with the recommendations of [Association Bulletin #22-03, Updated Recommendations on Donor Deferral for Use of Antiretroviral Medications for HIV Prevention and Treatment including Long-Acting Injectable PrEP and the Impact on Blood Safety](#);
- Assesses donor eligibility for individuals taking antiretroviral medications to prevent sexual transmission of human immunodeficiency virus (HIV), or for treatment of HIV infection:
 - Pre-exposure prophylaxis (PrEP) taken by mouth (oral) and by injection
 - Post-exposure prophylaxis (PEP)
 - Antiretroviral therapy (ART)

[PDF](#), [Word](#)

[Toolkit and Example Documents for Use with DHQ v2.1](#): includes examples of an acceptable approach for implementation of the recommendations in [Association Bulletin #22-03](#).

[FDA Recognized aDHQ v2.1](#)

- Accepted by FDA but does not include PrEP/PEP/ART
- AABB does not recommend using aDHQ v2.1 without PrEP/PEP/ART

[PDF](#), [Word](#)